The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
about
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Metformin and body weightDipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitusGlucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferationRegulation of glucose homeostasis by GLP-1Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetesPharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteersMode of administration of dulaglutide: implications for treatment adherenceIncreasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?Is GLP-1 a hormone: Whether and When?Mechanisms underlying glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretionPharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agentsA clinical perspective of obesity, metabolic syndrome and cardiovascular diseaseStimulation of incretin secreting cellsSystematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitorsPotentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitusDipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three StudiesIncretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitorsVascular repair strategies in type 2 diabetes: novel insightsMultiple Factors Related to the Secretion of Glucagon-Like Peptide-1Incretin physiology and pathophysiology from an Asian perspectiveHypothalamic Obesity in Craniopharyngioma Patients: Disturbed Energy Homeostasis Related to Extent of Hypothalamic Damage and Its Implication for Obesity InterventionThe Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including AtherosclerosisExenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectivesA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyondAlternative Medicine in Diabetes - Role of Angiogenesis, Oxidative Stress, and Chronic InflammationMetabolomics applied to the pancreatic isletLink between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatmentGlucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of strokeCardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapiesGLP-1-based strategies: a physiological analysis of differential mode of actionSystems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor SystemLixisenatide as add-on therapy to basal insulinTranslational implications of the β-cell epigenome in diabetes mellitusEffects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysisDiagnosing and managing diabetes in HIV-infected patients: current conceptsRole of plasma kallikrein in diabetes and metabolismMilk proteins, peptides, and oligosaccharides: effects against the 21st century disordersClinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combinationPhysiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease
P2860
Q22241288-6386D5A5-D714-4BAD-A748-CB78DFD194B3Q22250988-4EEED364-4561-4D3B-88BC-520AB1C6D07FQ24243196-99BDA843-CF6A-46C5-AF6D-D0B5AB37DA7BQ24307581-2A036ADA-1F8F-4D4D-BBBF-6B798C8BE356Q24563430-0CE6C6AD-A6A9-4C58-8C77-2FFB258AC02EQ24628948-7A93E19B-1FCB-48CD-87E1-4AC7CD3D4964Q24658008-4A29963B-7B7B-46DA-AD6B-7B9B4206B980Q26744065-A667EED1-7559-4F2A-A970-1BFCED62D190Q26744254-54A8D7C5-B947-42FF-AE9B-0E6DFCA25D94Q26749196-6E4FAD90-22F0-4C4D-A80A-819B4E56C7C3Q26749219-CF299674-F3B8-4A61-906E-B8729289D6C5Q26751138-7C8E06FE-038F-4CF5-87F1-5B4ADF26CE41Q26753121-CB658964-C4A9-415E-9A2A-5C527B9ECA88Q26765259-C72C8612-59AE-4479-86D9-06A861DF027FQ26772081-3F25115A-AD0D-4424-ABF3-37ABCA858A49Q26774021-42FB0118-C15E-4BFA-99AA-0452D7C88FBEQ26777177-F0E449F7-AF57-4FB3-A2E9-CF41A5D98FECQ26778608-088D13A0-EF9F-4D6F-A229-A65FD0934C7CQ26778658-A57981AB-6CD3-4DF5-96DC-A5FD9FB38AA8Q26781127-5F208956-C0E7-47A6-9B6E-CEA0406234D4Q26784623-596F30BF-38AB-4914-AC10-99FC58BA391BQ26786921-10FC3DA2-7861-43A8-A83A-B1FE6FB9E615Q26795473-7F6B64D2-7861-4320-95F8-199350D269ACQ26797236-C99DA011-A39F-4BF7-BF77-E68ADBC35D29Q26799389-A6D7491A-FAA1-4D8B-B3BD-23CB7B52E6A5Q26801343-6A138D98-DF9B-42E2-A8AC-B73E52E8B4D2Q26824852-D363581B-57BB-47A3-806D-B0E158224BEEQ26860246-34BB3961-A73E-4741-B4DD-0FC28AFE79B9Q26861493-6393D5BC-0955-476F-9A17-D492FBB3A689Q26866958-CE135670-1FEB-4160-B112-D8408BE7465DQ26997149-D6BDCB2B-3E63-44C7-A8ED-73743AB58B91Q26999386-602AA9CB-93EB-4952-AA2D-5318D772F219Q27007547-8EEC7B98-0CAD-4487-8F98-5B1A78D29DA7Q27009451-FF455245-6BC8-4805-AA11-2428A8470643Q27012696-4082AB67-5C4C-4A63-A0FB-3D83DC1A01B1Q27014697-EBF27A2E-C8C0-41C8-86B3-F946F5B972E0Q27016431-49A72BF3-5E42-43F8-8C71-2FAE2A29422BQ27023113-6E53DBCB-1F87-4BBA-9795-269490972794Q27026211-7F3FB626-1A2F-464E-993A-EBA5E5AF2756Q27027920-F66B4DA9-8307-4D89-9DBE-BC44EC5D1D12
P2860
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The incretin system: glucagon- ...... inhibitors in type 2 diabetes
@ast
The incretin system: glucagon- ...... inhibitors in type 2 diabetes
@en
The incretin system: glucagon- ...... inhibitors in type 2 diabetes
@nl
type
label
The incretin system: glucagon- ...... inhibitors in type 2 diabetes
@ast
The incretin system: glucagon- ...... inhibitors in type 2 diabetes
@en
The incretin system: glucagon- ...... inhibitors in type 2 diabetes
@nl
prefLabel
The incretin system: glucagon- ...... inhibitors in type 2 diabetes
@ast
The incretin system: glucagon- ...... inhibitors in type 2 diabetes
@en
The incretin system: glucagon- ...... inhibitors in type 2 diabetes
@nl
P3181
P1433
P1476
The incretin system: glucagon- ...... inhibitors in type 2 diabetes
@en
P2093
Michael A Nauck
P304
P3181
P356
10.1016/S0140-6736(06)69705-5
P407
P577
2006-11-11T00:00:00Z